JAK-STAT Signalling and Cytokines: The What, How, and Why

Key takeaways

• There are four JAKs: JAK1, JAK2, JAK3 and TYK2. TYK2 is not called JAK4 — no such protein exists.
• Cytokine receptors have no intrinsic kinase activity. Neither type I nor type II does. That is precisely why they depend on non-covalently associated JAKs, and it is the defining feature of the receptor class.
• Unphosphorylated STATs are predominantly cytoplasmic monomers. Phosphorylation drives dimerisation through reciprocal SH2-phosphotyrosine binding, and that dimerisation is the activation step.
• The pathway is unusually short — receptor to nucleus with no second messenger and no kinase cascade — which is why it is fast and why it needs strong negative regulation.
• SOCS proteins provide that brake: they are themselves STAT target genes, forming a classic negative feedback loop.
• JAK2 V617F is the defining mutation of the myeloproliferative neoplasms and the reason ruxolitinib exists.
• JAK inhibitors are effective in rheumatoid arthritis, psoriasis, IBD and alopecia areata, and carry class boxed warnings for serious infection, thrombosis, major cardiovascular events and malignancy.

Contents

• JAK proteins
• STAT proteins
• The pathway step by step
• Cytokine receptors
• Which cytokine uses which JAK and STAT
• Negative regulation
• Disease associations
• JAK inhibitors
• Measuring pathway activity
• Choosing antibodies
• Frequently asked questions

JAK-STAT antibodies

The kinases, the principal STATs, the phospho-site that reports activation, and SOCS3 for the feedback arm.

JAK1

JAK1 Rabbit Monoclonal Antibody

Rabbit mAbWB / IHC

Pairs with almost every other JAK; used by the gp130, common gamma chain and interferon receptor families.

View product →

JAK2

Anti-JAK2 [R03-1F2] Monoclonal Antibody

MonoclonalWB / IHC

Carries the V617F mutation of the myeloproliferative neoplasms and serves the erythropoietin and growth hormone receptors.

View product →

STAT1

STAT1 Rabbit Polyclonal Antibody

Rabbit pAbWB / IHC

The interferon-responsive STAT; central to antiviral and antimycobacterial immunity.

View product →

STAT3

STAT3 Rabbit Polyclonal Antibody

Rabbit pAbWB / IHC

The IL-6 family STAT, constitutively active in many tumours and mutated in hyper-IgE syndrome.

View product →

p-STAT3 Y705

Anti-Phospho-STAT3 (Tyr705) Monoclonal Antibody

MonoclonalWB / IF

Tyr705 phosphorylation is the activation event — the direct readout of pathway engagement.

View product →

SOCS3

SOCS3 Antibody

PolyclonalWB / IHC

The induced feedback inhibitor; measuring it reports whether the brake has engaged.

View product →

JAK proteins

JAK stands for Janus kinase, named after the two-faced Roman god because each enzyme carries two kinase-like domains. All four are non-receptor tyrosine kinases that sit constitutively bound to the cytoplasmic tails of cytokine receptors.

To be explicit on a common error: the fourth kinase is TYK2, and it is not designated JAK4. No protein of that name exists.

Each JAK has a FERM domain and an SH2-like domain that mediate receptor binding, followed by a pseudokinase domain and a catalytically active kinase domain. The pseudokinase domain is not merely vestigial — it autoinhibits the active domain, and the V617F mutation of JAK2 falls within it, relieving that inhibition.

STAT proteins

STAT stands for signal transducer and activator of transcription — a name that captures the unusual point that one protein performs both roles. Seven exist in mammals, from six genes: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6.

Each has an N-terminal domain, coiled-coil domain, DNA-binding domain, linker, SH2 domain and a C-terminal transactivation domain, with a single critical tyrosine between the SH2 and transactivation domains.

Monomer, not pre-formed active dimer

Unphosphorylated STATs are predominantly cytoplasmic monomers. On phosphorylation of that critical tyrosine, the SH2 domain of one STAT binds the phosphotyrosine of another, and the reciprocal interaction locks them into a parallel dimer that exposes a nuclear localisation signal.

Dimerisation is therefore the activation step, not a pre-existing state. Some unphosphorylated STAT does exist as antiparallel dimers with distinct functions, but describing STATs as sitting in the cytoplasm as inactive dimers omits the mechanism that actually switches the pathway on.

The pathway step by step

• Ligand binding. A cytokine binds its receptor, bringing two or more receptor chains — and their associated JAKs — into proximity.
• JAK activation. The apposed JAKs trans-phosphorylate one another on activation-loop tyrosines, relieving pseudokinase autoinhibition.
• Receptor phosphorylation. Active JAKs phosphorylate tyrosines on the receptor cytoplasmic tail, creating SH2 docking sites.
• STAT recruitment. STATs dock at those receptor phosphotyrosines through their own SH2 domains. Which STAT is recruited depends on the sequence around each site, and this is where much of the pathway’s specificity resides.
• STAT phosphorylation and dimerisation. JAKs phosphorylate the critical STAT tyrosine; two phosphorylated STATs form a reciprocal SH2-phosphotyrosine dimer.
• Nuclear translocation and transcription. The dimer enters the nucleus and binds GAS or ISRE elements, activating or repressing target genes.

What is notable is the absence of anything in between. No second messenger, no kinase cascade — the receptor and the transcription factor are separated by a single phosphorylation event. That directness makes the pathway fast, and makes tight negative regulation essential.

Cytokine receptors

An important correction to a common misstatement: cytokine receptors possess no intrinsic kinase activity of their own. This applies to both type I and type II. It is the defining property of the class and the entire reason JAKs are required — a receptor tyrosine kinase such as EGFR phosphorylates its own tail, whereas a cytokine receptor cannot and must borrow a kinase.

Both classes signal identically in mechanism — associated JAKs, receptor phosphorylation, STAT recruitment. The type I/type II division is structural, not functional.

Many receptors also share subunits: the common gamma chain across IL-2, 4, 7, 9, 15 and 21, and gp130 across the IL-6 family. Shared subunits explain both the redundancy between cytokines and the breadth of effect when one is blocked.

Which cytokine uses which JAK and STAT

These pairings explain inhibitor selectivity. A JAK3-sparing inhibitor leaves common gamma chain signalling largely intact; a TYK2-selective agent targets IL-12 and IL-23 without touching erythropoietin, which depends on JAK2.

Negative regulation

Because the pathway is so direct, it requires strong brakes. Three mechanisms operate, and the original article omitted all of them.

• SOCS proteins. The suppressor of cytokine signalling family are themselves STAT target genes — so activating the pathway induces its own inhibitor. SOCS bind phosphotyrosines on the receptor, block STAT docking, inhibit JAK catalysis directly, and recruit an E3 ubiquitin ligase to degrade the complex. A textbook negative feedback loop.
• Protein tyrosine phosphatases — SHP1, SHP2, CD45 and PTP1B — remove the activating phosphates from JAKs, receptors and STATs.
• PIAS proteins act in the nucleus, blocking DNA binding by activated STAT dimers.

Loss of these brakes matters: SOCS silencing is a recognised route to constitutive STAT3 activation in tumours, achieving the same end as an activating mutation.

Disease associations

The STAT1 versus STAT3 distinction in the immunodeficiencies is worth holding onto, since the two are readily confused and point to entirely different clinical pictures.

JAK inhibitors

JAK inhibitors are small molecules that occupy the ATP-binding site of the kinase domain, preventing JAKs from phosphorylating the receptor and STATs. Several are approved, differing in which JAKs they hit.

Safety

As a class these agents carry boxed warnings for serious infection (including tuberculosis reactivation and herpes zoster), venous thromboembolism, major adverse cardiovascular events and malignancy. Because JAK2 also serves erythropoietin and thrombopoietin, cytopenias are a predictable on-target effect.

A correction on mechanism: JAK inhibition reduces signalling by cytokines that use this pathway — IL-6, the interferons, IL-2, IL-12 and IL-23. TNF-alpha is not a JAK-STAT cytokine; it signals through NF-kappa-B and MAPK, so it is a poor example of what JAK inhibitors block. IL-6 is the appropriate one.

Clinical decisions rest with the treating clinician; this is research context only.

Measuring pathway activity

• Phospho-STAT by western blot or flow cytometry is the standard readout. Phospho-STAT3 at Tyr705 and phospho-STAT1 at Tyr701 are the usual targets, always normalised to total STAT.
• Timing matters. STAT phosphorylation peaks within 15 to 30 minutes of stimulation and declines as SOCS is induced, so a late time point can look like no response at all.
• SOCS induction at the mRNA or protein level confirms the pathway ran to completion rather than merely being triggered.
• Phospho-flow resolves responses cell by cell, which matters in mixed populations where different cells express different receptor combinations.
• Target gene readouts — interferon-stimulated genes, acute phase proteins — report the transcriptional consequence rather than the signalling event.

Frequently asked questions